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1. General Introduction 
Lamellar vesicles are promising drug delivery systems for several 
pharmaceutical applications and different administration routes. In 
fact, they offer some advantages over classical dosage forms. 
Lamellar vesicles can be divided in two main classes: phospholipids 
vesicles, called liposomes and introduced by Sir Bangham in 1960 and 
non-ionic surfactant vesicles, called niosomes as introduced by 
laboratories l'Oreal in 1970s. 
Over the last two decades, the lack of ability of conventional 
liposomes and niosomes to efficiently deliver drugs through the skin 
has led to intensive research with the introduction and development of 
new classes of lipid vesicles. 
In the early 1990s, the so called elastic, highly deformable or ultra 
flexible vesicles were introduced with the aim to improve (trans) 
dermal drug delivery. 
In particular, Transferosomes, introduced by Cevc et al., were the first 
generation of this new class of lipid vesicles. As with conventional 
liposomes, they mainly consist of phospholipids but also contain a 
surfactant (sodium cholate, sodium deoxycholate, different Spans and 
Tweens, dipotassium glycyrrhinizate) that acts as an “edge activator” 
capable of destabilizing the lipid bilayer thus increasing its 
deformability (1). 
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A second generation of elastic vesicles, mainly consisting of non-ionic 
surfactants, was introduced in 1999 by van den Bergh (2). Touitou in 
2000 developed ethosomes (3), new soft vesicular carriers mainly 
consisting of phospholipids, water and ethanol in high amount (20-
45%). The ethosomes are able to stably encapsulate and protect 
several drugs and increase their dermal accumulation and transdermal 
passage (4). 
For several years, the group of Technologies for Drug Delivery of the 
University of Cagliari has been studying delivery of several drugs by 
liposomes and niosomes. More recently, the group, has introduced the 
so called Penetration Enhancer-containing Vesicles (PEVs), liposomes 
containing in their composition a penetration enhancer (PE), as 
carriers for (trans)dermal delivery of different drugs (5-12). During 
these years, PEVs have been prepared using various PEs, of different 
physicochemical properties and mechanism of enhancement, with the 
aim of finding new stable and efficient vesicular carrier for drug 
delivery. Moreover, vesicle coating with suitable hydrophilic 
polymers such as polysaccharide hydrogels, largely studied for their 
biocompatibility and great versatility in modified drug release, have 
been studied. In particular, the coating of liposomes with chitosan was 
found to increase vesicle stability as well as to provide them with 
mucoadhesive properties (13-15). Thanks to its protective effect, this 
approach allowed the group to test liposomes for different application 
such as oral and pulmonary delivery of drugs. 
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Taking account previous results obtained by my research group, in my 
thesis research novel vesicular formulations (liposomes and PEVs) are 
presented for skin delivery of quercetin and phycocyanin, and chitosan 
coated liposomes (called chitosomes) are proposed for curcumin 
pulmonary delivery. 
Natural antioxidant and anti-inflammatory drugs have received a great 
deal of attention in recent years for their therapeutic potential for 
several diseases and low toxicity. The emerging view is that many 
natural drugs are likely to exert multiple pharmacological effects, in 
particular the antioxidant and anti-inflammatory properties of these 
three selected natural drugs have been described by several authors. 
Unfortunately, the effective efficiency of these naturals is 
substantially limited by their in vivo low bioavailability. Actually, 
their gastro-intestinal absorption after oral administration is limited by 
their low solubility, permeability and/or instability in the 
gastrointestinal tract (pH, enzymes, presence of other nutrients). As a 
consequence, their bioavailability at action site is, usually, not enough 
to exert an effective pharmacological effect, thus, limiting their 
potential health benefits. 
Local administration of these natural drugs into innovative, 
phospholipids, lamellar vesicles allows circumventing these 
drawbacks, and would appear to be a promising approach to increase 
drug bioavailability at action site. In particular, quercetin and 
phycocyanin can be administrate in the skin to facilitate local drug 
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delivery to the skin and deeper soft tissues (subcutaneous adipose and 
skeletal muscle tissue), preventing their systemic side effects. 
Topical delivery of drugs has several advantages over other traditional 
routes of administration, including improved bioavailability for drugs 
that suffer gastrointestinal environment and/or hepatic first effects. 
However, the barrier nature of the stratum corneum (SC) represents a 
significant obstacle for most drugs to be delivered to and through the 
skin (14). The flattened, anuclear and protein rich corneocytes of the 
SC are densely packed within the extracellular lipid matrix, which is 
arranged in bilayers (13). This is often referred to as a ‘bricks and 
mortar’ arrangement (15). The corneocytes are held together by 
corneodesmosomes. 
Dermal and transdermal delivery requires efficient penetration of 
active compounds through the skin barrier by a passive diffusion 
process. A molecule applied on the skin surface may use two diffusion 
routes to penetrate: the transappendegeal and the transepidermal 
routes. 
The transappendageal route includes transport via the sweat glands 
and hairfollicles with their associated sebaceous glands. Although 
these routes were traditionally considered of minor importance 
because of their relatively small area, recent research has indicated 
that the pilosebaceous units may contribute significantly to topical 
drug delivery by acting as low resistance pathway for ions and large 
polar molecules which hardly permeate through the stratum corneum. 
1.0. General Introduction 
10 
 
Moreover, the hair follicles and sebaceous glands are associated with 
various dermatological disorders such as acne, alopecia, and several 
skin tumours. Therefore, there is a great interest in the pilosebaceous 
units as targets for localized drug delivery, as well as shunts for 
transdermal delivery, even if the specific role of the follicular pathway 
in dermal drug absorption is difficult to elucidate due to the lack of an 
adequate animal model to distinguish follicular to non-follicular 
transport. 
Through the epidermis there exist two pathways: the transcellular, 
across the corneocytes and the lipid matrix, and the intercellular 
across the lipid domains between the corneocytes. 
Structure and barrier function of the skin have been extensively 
described in the literature and it is generally accepted that the 
intercellular route provides the principal pathway for the permeation 
of most drugs. 
Molecules are able to move freely within the intercellular spaces and 
diffusion rates are governed by their physicochemical properties such 
as molecular weight or volume, solubility and hydrogen bonding 
ability (17). However, the free movement of macromolecules may be 
physically restricted within the lipid channels, which have been 
estimated by van de Merwe et al. to be 19 nm (18) and by Baroli et al. 
to be 75 nm (19). This suggests that for such materials, the SC could 
represent an additional barrier that is not present for small molecules. 
.
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2. Effect of penetration enhancer 
containing vesicles on the percutaneous 
delivery of quercetin through new born 
pig skin. 
2.1.  Introduction  
Quercetin (3,3′,4′,5,7-pentahydroxyflavone, QUE) is a bioflavonoid 
profuse in nature in plant food sources. It exerts multiple 
pharmacological effects, including potent anti-oxidant activity in vivo, 
induction of apoptosis, modulation of cell cycle, anti-mutagenesis, 
inhibition of angiogenesis, and anti-inflammatory effect. Recently, it 
has been reported that the topical application of quercetin inhibits 
oxidative skin damage and the inflammatory processes induced by 
solar UV radiation (20). Topical use of quercetin is frequently 
hampered by its low skin permeability and poor solubility in aqueous 
media, which make the development of pharmaceutical formulations 
difficult. Different strategies, such as prodrug (21), microemulsion 
(22), have been used to improve quercetin topical delivery. 
In this work, novel quercetin vesicular formulations are presented for 
skin delivery. Aiming at incorporating quercetin into phospholipid 
vesicles, four different hydrophilic penetration enhancers (PEs), 
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essential to improve quercetin solubility in water due to their high 
solubilizing power, were selected and used to formulate quercetin-
loaded Penetration Enhancer containing Vesicles (PEVs). PEV 
formulations were prepared using 60 mg/ml of a mixture of soy lipids 
(Phospholipon 50, P50) and one of the selected PEs: Transcutol® P 
(Trc), propylene glycol (PG), polyethylene glycol 400 (PEG), and 
Labrasol® (Lab). The use of a mixture of PE/water (40% v/v) as 
hydrophilic phase, enabled the incorporation of 2 mg/ml of QUE in 
PEVs without any sign of drug precipitation, during or after 
fabrication. Previous findings demonstrated that PEVs are powerful 
enhancers for dermal delivery, due to the synergistic effect of 
phospholipid vesicles and PE (23, 27). The latter may increase fluidity 
of the lipid portion of the stratum corneum, facilitating the delivery of 
the vesicle loaded-drug, and its diffusion through the skin. Given that, 
quercetin-loaded PEVs were prepared, thoroughly characterized by 
size, surface charge, loading capacity, morphological and viscoelastic 
features. Moreover, their penetration capability and distribution 
through pig skin were assessed by Franz diffusion experiments and 
confocal microscopy, to give further evidence of the superior 
performances of PEVs. 
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2.2. Experimental section 
2.2.1. Materials 
Soybean lecithin (Phospholipon® 50, P50, with 45% 
phosphatidylcholine and 10-18% phosphatidylethanolamine) was 
kindly supplied by AVG (Milan, Italy) and Lipoid GmbH 
(Ludwigshafen, Germany). 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) 
ammonium salt (rhodamine-phosphoethanolamine, Rho-PE) was 
purchased from Lipoid GmbH (Ludwigshafen, Germany). Diethylene 
glycol monoethyl ether (Transcutol® P, Trc) and caprylocaproyl 
macrogol 8-glyceride (Labrasol®, Lab) were a gift from Gattefossè 
(Saint Priest, France). Propylene glycol (PG), polyethylene glycol 400 
(PEG), quercetin (QUE) and all the other products were of analytical 
grade and were purchased from Sigma-Aldrich (Milan, Italy). 
 
2.2.2. Vesicle preparation 
QUE (2 mg/ml) was dissolved in a PE/water solution (40% v/v) and 
added to the flask containing P50 (60 mg/ml). Lipids were left 
swelling in the solution overnight (28, 29). Sonicated vesicles were 
prepared by sonicating for 3 minutes (2 seconds on and 2 seconds off) 
the dispersions with a Soniprep 150 ultrasonic disintegrator (MSE 
Crowley, UK). 
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Each vesicle suspension was purified from the non-incorporated drug 
by exhaustive dialysis against distilled water at 4 °C for 1 hour, using 
dialysis tubing (Spectra/Por® membranes: 12–14 kDa MW cut-off, 3 
nm pore size; Spectrum Laboratories Inc., USA). Incorporation 
efficiency (E%), expressed as the percentage of the amount of QUE 
initially used, was determined by high performance liquid 
chromatography (HPLC) after disruption of vesicles with 0.025% 
non-ionic Triton X-100. QUE content was quantified at 255 and 367 
nm using a chromatograph Alliance 2690 (Waters, Italy). The column 
was a SunFire C18 (3.5 µm, 4.6x150 mm). The mobile phase was a 
mixture of acetonitrile, water and acetic acid (94.8:5:0.2, v/v), 
delivered at a flow rate of 1.0 ml/min. 
 
2.2.3  Vesicle characterization 
Vesicles were characterized by Transmission Electron Microscopy 
(TEM) for vesicle formation and morphology. A drop of the vesicular 
dispersion was applied to a carbon film-covered copper grid and 
stained with a 1% phosphotungstic acid. Then, samples were 
examined with a JEM-1010 (Jeol Europe, France) transmission 
electron microscope equipped with a digital camera MegaView III and 
Software "AnalySIS", at an accelerating voltage of 80 kV. 
The average diameter and polydispersity index (P.I.) of the samples 
were determined by Photon Correlation Spectroscopy (PCS) using a 
2.0. Quercetin 
15 
 
Zetasizer nano-ZS (Malvern Instrument, UK). Samples were 
backscattered by a helium–neon laser (633 nm) at an angle of 173° 
and a constant temperature of 25 °C. The P.I. was used as a measure 
of the width of the size distribution: P.I. less than 0.4 indicates a 
homogenous and monodisperse population. Zeta potential was 
estimated using the Zetasizer nano-ZS by means of the M3-PALS 
(Phase Analysis Light Scattering) technique, which measures the 
particle electrophoretic mobility in a thermostated cell. All the 
samples were analysed 24 hours after their preparation. 
 
2.2.4  Rheological studies 
Steady shear tests and dynamic oscillatory tests were performed with a 
controlled strain and stress rheometer (Kinexus pro, Malvern 
Instruments, UK) equipped with a rSpace data acquisition software. 
Samples were allowed to rest for at least 300 seconds prior to 
analyses. Analyses were carried out using a double-gap concentric 
cylinder DG25 (also called Couette or Coaxial geometry). The test 
dispersion is maintained in the annulus between the cylinder surfaces. 
The double-gap configuration is useful for low-viscosity dispersions, 
as it increases the total area, and therefore the viscous drag, on the 
rotating inner cylinder, and increases the accuracy of the 
measurement. 
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Viscometry experiments were conducted in a shear range of 0.01-10 
Pa. Frequency sweep tests were performed from 0.01 to 10 Hz, and at 
a shear stress of 0.5 Pa. The oscillatory parameters used to compare 
the viscoelastic properties of the different dispersions were the storage 
modulus (G'), which represents the elastic part of the response (where 
energy is stored and used for elastic recoil of the specimen when a 
stress is removed), the loss modulus (G″), which represents the 
viscous response (where energy is dissipated and the material flows) 
(30). All measurements were made in triplicate, at a constant 
temperature of 25 °C. 
 
2.2.5. Ex vivo skin penetration and permeation studies 
Experiments were performed non-occlusively using Franz diffusion 
vertical cells with an effective diffusion area of 0.785 cm2, and new 
born pig skin. One-day-old Goland–Pietrain hybrid pigs (~1.2 kg) 
were provided by a local slaughterhouse. The skin, stored at -80 °C, 
was pre-equilibrated in physiological solution (0.9% w/v of NaCl) at 
25 °C, two hours before the experiments. Skin specimens (n = 6 per 
formulation) were sandwiched securely between donor and receptor 
compartments of the Franz cells, with the stratum corneum (SC) side 
facing the donor compartment. The receptor compartment was filled 
with 5.5 ml of physiological solution, which was continuously stirred 
with a small magnetic bar and thermostated at 371 °C throughout the 
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experiments to reach the physiological skin temperature (i.e. 321 
°C). One hundred microliters of the tested vesicle suspensions, or 
coarse dispersions of P50, PE and free QUE, were placed onto the 
skin surface. At regular intervals, up to 8 hours, the receiving solution 
was withdrawn and replaced with an equivalent volume of pre-
thermostated (37°C) physiological fresh solution, to ensure sink 
conditions. Withdrawn receiving solutions were analyzed by HPLC 
for drug content. 
After 8 hours, the skin surface of specimens was gently washed (3 
times) with 1 ml of distilled water, then dried with filter paper. The 
SC was removed by stripping with adhesive tape Tesa
®
 AG 
(Hamburg, Germany). Each piece of the adhesive tape was firmly 
pressed on the skin surface and rapidly pulled off with one fluent 
stroke. Ten stripping procedures were performed consecutively. 
Epidermis was separated from dermis with a surgical sterile scalpel. 
Tape strips, epidermis, and dermis were cut and placed each in a flask 
with methanol and then sonicated for 4 minutes in an ice bath to 
extract the drug. The tapes and tissue suspensions were centrifuged for 
10 minutes at 10000 rpm, and then the supernatants were filtered and 
assayed for drug content by HPLC. 
2.2.6. Confocal Laser Scanning Microscopy 
 
PEVs were made fluorescent by adding Rhodamine-
phosphoethanolamine during the preparation. This labelling allows 
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visualizing the penetration of the lipid bilayer materials through new 
born pig skin. (Trans)dermal study was carried out at the same 
conditions reported in paragraph 2.5. After 8 h of treatment, the skin 
specimens were washed, the diffusion area punched out, and rapidly 
frozen at -80 °C. Sections of skin (7 µm thickness) were cut with a 
cryostat (Leica CM1950, Barcelona, Spain) orthogonally (in the z 
axis) to the surface, and examined to investigate the fluorescent probe 
distribution in the different skin strata. Analyses were carried out 
using a FluoView FV1000 inverted confocal microscope (Olympus, 
Barcelona, Spain) equipped with a Ultraviolet/Visible light laser. 
Using a UPlanSApo 20x objective NA 0.75, images with a field size 
of 1024 × 1024 µm were generated. Rhodamine was excitated at 559 
nm, and detected at 578 nm. The instrument offers a revolutionary 
synchronized laser scanning system, called the SIM Scanner: while 
one laser stimulates, the second laser simultaneously provides high-
resolution imaging, which enables the acquisition of images showing 
the distribution of the marker among skin structures. 
 
2.2.7. Statistical analysis of data 
Data analysis was carried out with the software package R, version 
2.10.1. Results are expressed as the mean  standard deviation. 
Multiple comparisons of means (Tukey test) were used to substantiate 
statistical differences between groups, while Student’s t-test was 
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applied for comparison between two samples. Significance was tested 
at the 0.05 level of probability (p). 
 
2.3. Results and Discussion 
In this study, we prepared and characterized phospholipid vesicles 
containing in the water phase high quantities of different PEs (40%), 
required to avoid quercetin (2 mg/ml) precipitation. Indeed, we aimed 
at investigating PEs capability to act as solubilizers for poorly water 
soluble QUE, and as penetration enhancers for improved 
(trans)dermal delivery of the drug, synergically with the vesicular 
carrier system. To this purpose, four different safe, biocompatible, 
largely used in topical preparations PEs, namely PG, PEG, Lab and 
Trc were used to formulate as many PEV dispersions, together with 
P50, a mixture of soy lipids. 
 
2.3.1. Vesicle design and characterization 
As mentioned, owing to the extremely poor aqueous solubility of 
quercetin, a novel delivery approach was designed, that is the 
preparation of vesicular dispersions. It is noteworthy that it was not 
possible to obtain conventional phospholipid liposomes (i.e. P50 and 
QUE in water) with favourable characteristics, due to drug 
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precipitation. On the contrary, using PE/water blends, novel PEVs 
were successfully produced. 
Vesicle formation in the presence of the PE was confirmed by TEM 
(Figures 1a-d). PEVs were always multilamellar, showing an irregular 
and ovoidal shape, except PG-PEVs. 
Mean size of PEVs, measured by PCS, was closely related to their 
composition (Table 1): vesicles containing Trc and PEG were 
approximately 2.5-3-fold larger than PG- and Lab-PEVs, being around 
200 nm the former, and 80 nm the latter. This is clearly in accordance 
with TEM observation. The difference in size between empty and 
corresponding QUE-loaded vesicles was related to the composition of 
the samples: empty and QUE-loaded PEG-PEVs showed the same 
mean size; loaded PG- and Trc-PEVs were larger than the empty ones; 
loaded Lab-PEVs were smaller than the corresponding empty vesicles. 
PEVs were quite homogeneously dispersed and values were always 
repeatable. Zeta potential values were always highly negative (around 
−50 mV), indicative of a good storage stability against vesicle 
aggregation and fusion. Lab-PEVs showed a lower zeta potential 
(around −30 mV), with and without the drug. QUE incorporation into 
the vesicles at a percentage ranging from 48 to 75 was achieved by the 
prepared formulations (E%; Table 1), showing their good loading 
capacity, which was affected by the used PE. PEG-, PG- and Trc-
PEVs showed the lowest E%, as a function of their high hydrophilicity 
(Pow = 0.000015, 0.12 and 0.7, respectively). 
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The used PEs are characterized by a relatively high hydrophilicity and 
show good solvent capability for QUE. However, as a consequence of 
their molecular structure, the corresponding obtained PEVs exhibited 
somewhat different features (e.g. size, E%), presumably by virtue of 
specific interactions with the components of the formulations, related 
to peculiar properties, such as polarity, partition coefficient, and 
ability to interpenetrate the lipids. 
 
2.3.2. Rheological behaviour 
Macroscopic rheological properties of samples, such as viscosity, 
elastic or viscous moduli, depend on the strength of particle-particle 
interactions that occur at supramolecular level, and reflect changes in 
the microstructure of lamellar vesicles. The vesicle dispersions 
showed the rheological features normally observed in multilamellar 
vesicle dispersions. The behaviour of the different PEVs on the shear 
rate against shear stress was first examined (Figure 2). For all 
samples, the shear rate increased when the shear stress increased, and 
shear viscosity (= shear stress/shear rate) was independent of the 
applied shear stress, like for Newtonian fluids. Indeed, in a Newtonian 
fluid, the relation between the shear stress and the shear rate is linear, 
the constant of proportionality being the coefficient of viscosity. The 
viscosity of PEVs was higher than that of water (1 mPa s): 
approximately 5, 6, 9 and 40 mPa s for Trc-, PG-, PEG- and Lab-
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PEVs, respectively. This increase in viscosity is due to the existence 
of vesicular lamellar structure occupying a high hydrodynamic 
volume, especially for Lab-PEVs, that showed a smaller size, lesser 
number of bilayers, and an increased volume fraction occupied by the 
vesicles, closely related with the increase of viscosity. 
In addition, we performed oscillatory frequency experiments to 
determine the storage (G’) and the loss (G”) response of the vesicular 
dispersions to the applied force. In figure 3 representative mechanical 
spectra of samples are plotted against frequency, in comparison with 
water. It was found that Trc-PEVs, as well as PG- and PEG-PEVs, 
disclosed the same behaviour of water, a purely viscous fluid. For 
these formulations, elastic modulus increased uniquely due to the 
inertia effect, while the viscous modulus was a little higher than that 
of water, as evidenced by the viscometry study. On the contrary, Lab-
PEVs showed a higher loss modulus (by about 1 order of magnitude 
with respect to water) and a storage modulus only slightly higher than 
that of water, indicating the presence of an elastic component, even if 
the viscous one predominated. 
Further, it was evident that the loss modulus (G”) was significantly 
higher (by about 3 orders of magnitude) than the storage modulus (G’) 
throughout the employed frequency range, confirming the viscous 
nature of PEVs. The smaller magnitude of the elastic modulus 
indicates weak particle–particle interactions. Therefore, the samples 
showed the typical behaviour of diluted spherical multilamellar 
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vesicle dispersions, where the storage modulus is lower than the loss 
modulus (G’ < G”) (31), indicating the viscous nature of the samples. 
Each sample showed different values of viscosity, storage and loss 
moduli because the different PEs in the vesicle dispersions caused 
different degrees of swollen lamellar phase. 
These results are consistent with the nature of the tested samples: they 
are diluted dispersions, which behave as ideal Newtonian fluids that 
simply flow when subjected to a stress, as they are non-structered 
systems with weak vesicle interactions. On the other side, the presence 
of labrasol probably makes the vesicular bilayer more deformable, 
resulting in an increase of the elastic component. 
 
2.3.3. Ex vivo skin penetration and permeation studies 
The skin penetration ability of quercetin loaded in PEVs was probed 
by ex vivo Franz diffusion studies on new born pig skin. The amount 
of drug accumulated into stratum corneum, epidermis, and dermis is 
expressed as the percentage of the drug applied onto the skin. As 
illustrated in Figure 4a, all PEVs promoted QUE deposition in the 
three main skin strata, showing the same behaviour in all samples: the 
lowest drug accumulation in the stratum corneum, the highest in the 
epidermis, slightly higher in the dermis than in stratum corneum, and 
significantly lower in receptor fluid than in epidermis. In particular, 
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PG- and PEG-PEVs allowed the highest drug accumulation into (~ 
67%) and through (~ 27%) the skin. 
To clarify the role of the studied vesicles in (trans)dermal drug 
delivery, and in particular to elucidate if they act as carriers or 
penetration enhancers, coarse dispersions of the same composition 
used to produce vesicles were tested, too. As can be seen in Figure 4b, 
when the coarse dispersions were used, the drug accumulated in the 
skin layers was lower: about 6-fold for PG-, PEG- and Lab-PEVs, 20-
fold for Trc-PEVs, than that obtained with the corresponding QUE-
loaded vesicular formulations, or even nil in the stratum corneum in 
the case of PG- and PEG-PEVs treated skin. None of the coarse 
dispersions with free QUE was found to determine a systemic drug 
permeation. Results obtained confirm PEVs’ capability to behave as 
true carriers, and not simply as penetration enhancers (24, 25). 
 
2.3.4. Confocal Laser Scanning Microscopy (CLSM) 
PEVs were labelled with Rho-PE and applied onto pig skin for 8 
hours. The fate of the fluorescent bilayer materials through new born 
pig skin was visualized using the CLSM technique. Mechanical cross-
sections were made othogonally to the skin surface, to obtain a good 
estimation of distribution pattern of fluorescent phospholipids. These 
cross-sections provided on a single focal plane a simultaneous 
visualization of stratum corneum, viable epidermis and dermis. Figure 
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5 consists of 4 cross-sections (~ 400 µm) of pig skin treated with 
labelled PEVs containing alternatively PG, PEG, Lab or Trc. Images 
indicate a high accumulation of Rho-PE in the SC (~ 70 µm in depth), 
since most of the vesicles penetrate into the stratum corneum and fuse 
with the intercellular lipids. Indeed, phospholipid vesicles disorder the 
complex structure of the upper intercellular lipid sheets, but also cause 
an occlusive effect, which helps hydratation of the keratin layer, 
resulting in an increased penetration. The free drug could easily 
penetrate into the viable epidermis, but also drug-loaded intact 
vesicles are facilitated in their passage through the skin, carrying and 
delivering the drug to the viable epidermis and dermis. Overall, 
fluorescence in the 4 skin cross-sections was always higher in SC than 
in epidermis and dermis; PEG-PEVs treated skin showed a high 
fluorescence also in epidermis; PG- and Trc-PEVs promoted Rho-PE 
accumulation in the dermis, whereas Lab-PEVs treated skin specimen 
showed only a slight fluorescence in the dermis. In the light of these 
findings, PEVs seem to be able to penetrate intact the skin reaching 
the lowest SC layers where they form a depot from which the drug can 
be released (24, 32, 33). 
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Table 1. Characteristics of empty and QUE-loaded PEVs: mean 
diameter (MD), polydispersity index (P.I.), zeta potential (ZP) and 
incorporation efficiency (E%). Each value represents the mean ± S.D., 
n = 6. 
 
  
MD 
(nm) 
P.I. ZP (mV) E (%) 
P50/PG Empty 52±10 0.36 -51±7  
 QUE 83±10 0.35 -63±4 57±8 
P50/PEG Empty 193±5 0.30 -51±2  
 QUE 190±4 0.31 -58±2 48±7 
P50/Lab Empty 135±10 0.27 -21±4  
 QUE 86±5 0.29 -32±3 75±9 
P50/Trc Empty 156±6 0.19 -51±6  
 QUE 226±5 0.28 -49±5 59±8 
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Figure 1. Negative stain electron micrographs of QUE-loaded PEVs 
prepared with: (a) propylene glycol, (b) PEG400, (c) labrasol, (d) 
transcutol. 
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Figure 2. Linear scale plots of shear rate vs shear stress for QUE-
loaded PEVs 
 
 
Figure 3. Frequency sweep spectra for PEVs: storage (G’) and loss 
(G”) moduli against frequency are shown 
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Figure 4. Determination of QUE deposition into pig skin layers (SC, 
stratum corneum; Ep, epidermis; D, dermis and RF, receptor fluid) 
after 8-h non-occlusive treatment: (a) QUE loaded in PEVs, (b) coarse 
dispersions of P50, PE 
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Figure 5. CLSM of cross-sections of new born pig skin treated for 8 
hours with PEVs labelled with rhodamine-phosphoethanolamine. PG, 
PEG, Lab and Trc were used to formulate PEV dispersions. 
PG    
PEG  
Lab   
Trc    
200 m 
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2.4. Conclusions 
In this study we used a high amount (40%) of hydrophilic PEs to 
facilitate QUE incorporation into phospholipid bilayer, and to avoid 
QUE precipitation in vesicle dispersions. Results underline the ability 
of PEs (propylene glycol, polyethylene glycol 400, labrasol and 
transcutol) to improve drug solubility in vesicle dispersion, but above 
all, to have a synergic effect with phospholipids as penetration 
enhancers, which make PEVs potent nanocarriers for QUE skin 
delivery.
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3.0. Development, characterization and 
ex vivo assessment of effective Penetration 
Enhancer containing Vesicles for dermal 
and deeper soft tissue delivery of 
phycocyanin on human skin 
 
3.1. Introduction 
Several studies have demonstrated the ability of topical fluid 
formulations to provide effective bioavailability of non-steroidal anti-
inflammatory drugs (NSAIDs) in soft tissue pain and damaged 
skeletal muscle tissue higher than that obtained after oral 
administration, along with a lower plasma bioavailability (34, 35) 
Different drug carrier systems have been proposed for improving and 
prolonging the NSAID bioavailability in the skin and deeper tissues 
after topical application, such as liposomes, niosomes and 
transfersomes (36, 38). These systems are able to optimize dermal 
penetration and targeting of drugs (39, 41). As alternative vesicular 
systems, Penetration Enhancer containing Vesicles have been 
developed. They offer the advantage of associating the favorable 
properties of phospholipid vesicles and penetration enhancers (42, 50). 
In the present study phycocyanin-encapsulating PEVs (PC; 232 kDa), 
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an anti-inflammatory protein, have been formulated to facilitate local 
drug delivery to the skin and deeper soft tissues (subcutaneous adipose 
and skeletal muscle tissue), preventing systemic side effects of the 
drug. Phycobiliproteins are water-soluble and fluorescent proteins 
derived from cyanobacteria and eukaryotic algae. PC is one of the 
main biliprotein of blue-green algae, such as Spirula (Arthospira) 
maxima, used in pharmaceutical research as radical scavenger in 
oxidative stress-induced diseases and as strong antioxidant and anti-
inflammatory (51). The antioxidant and anti-inflammatory properties 
of PC have been described by several authors (52, 55). Our previous 
studies showed that conventional phospholipid vesicles were capable 
of improving anti-inflammatory activity of PC in mice, in a dose 
dependent fashion. Indeed, liposomes were able to give the same anti-
inflammatory response as the free protein by using half PC dose (55). 
In this work, PC was obtained from a dry extract (AfaMax®) of green 
blue microalgae Klamath (Aphanizomenon Flos Aquae). PC 
extraction and purity were confirmed by gel electrophoresis (SDS 
PAGE), MALDI top-down sequencing, LC/MS and UV absorption. 
Purified PC was encapsulated in different phospholipid vesicles. In 
particular, PEVs were prepared using a commercial mixture of 
phospholipids (Phospholipon 50, P50) and Transcutol® P (Trc) or 
propylene glycol (PG). Conventional phospholipid liposomes and 
ethosomes were prepared with the same phospholipid mixture P50, 
and used as controls. All vesicular dispersions were tested aiming at 
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evaluating the influence of the vesicular encapsulation on ex vivo PC 
penetration into and permeation through human skin. PC vesicles were 
labelled with rhodamine and their penetration extent and localization 
in the skin strata were examined by confocal laser scanning 
microscopy (CLSM). Moreover, fixed and sectioned tissue samples 
were visualized in three-dimensional structure using Scanning 
Electron Microscopy (SEM) to gain a complete picture of skin 
architecture and skin-vesicle interactions (46, 56). 
 
3.2. Materials and Methods 
3.2.1. Materials 
Phospholipon
®
 50 (P50), a mixture of soy phospholipids (45% 
phosphatidylcholine and 10-18% phosphatidylethanolamine) was 
kindly supplied by AVG (Milan, Italy) and Lipoid GmbH 
(Ludwigshafen, Germany), and 1,2-dioleolyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (Rho-PE) 
was purchased by Lipoid GmbH (Ludwigshafen, Germany). 
Diethylene glycol monoethyl ether (Transcutol® P, Trc) was kindly 
provided by Gattefossè (Saint Priest, France). Ethanol (Et), propylene 
glycol (PG) and all the other products were of analytical grade and 
were purchased from Sigma-Aldrich (Milan, Italy). Phycocyanin (PC) 
was obtained from AfaMax®, an extract of AFA-phycocyanins from 
Klamath algae, from Nutratec (Urbino, Italy). 
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3.2.2. PC extraction and purification 
PC was extracted from AfaMax® following the method by Benedetti 
et al. with some modifications (57). AfaMax® was dissolved in 
phosphate buffer saline (PBS, pH 7.4), brought to 50% saturation by 
the addition of ammonium sulfate, and allowed to stand for 60 
minutes at 4 °C. The suspension was centrifuged (Heraeus Megafuge 
1.0R) for 90 minutes at 40000 rpm and 4 °C to remove any insoluble 
material. The clear colourless supernatant was eliminated, and the 
blue precipitate was dissolved in a small volume of PBS and dialysed 
(Spectra/Por® tubing, 12–14 kDa MW cut-off; Spectrum Laboratories 
Inc., DG Breda, The Netherlands) overnight at 4  C against the same 
buffer. Dialysed PC was purified by gel chromatography with 
Sepharose
®
 CL-4B pore size 60 – 20000 kDa (Sigma Aldrich, Milan, 
Italy), and the eluate lyophilized to obtain a blue powder to be loaded 
in vesicles, after the appropriate qualitative and quantitative testings. 
 
3.2.3. SDS PAGE and in-gel digestion 
The eluate from gel chromatography was separated on 15% sodium 
dodecyl sulphate polyacrylamide gels (SDS PAGE) using protein 
markers with a range of molecular weights from 10 to 250 kDa. 
Electrophoresis was run at 12 mA at room temperature, and the gel 
stained with Coomassie Brilliant Blue R-250 (Bio-Rad Laboratories, 
CA, USA). Bands of interest were cut from the gel and subjected to 
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enzymatic digestion with trypsin, according to Shevchenko et al.(58). 
The gel pieces were swollen in a digestion buffer containing 100 mM 
NH4HCO3 and 0.012 µg/µl in Ambic 10 mM of trypsin. After 45 
minutes the supernatant was removed and discarded, 20 µl of 50 mM 
NH4HCO3 were added to the gel pieces and digestion allowed to 
proceed at 37 °C for 3 hours. The supernatant containing tryptic 
peptides was dried by vacuum centrifugation. Prior to mass 
spectrometric analysis, the peptide mixtures were redissolved in 10 µl 
of 5% formic acid. 
 
3.2.4. Analysis of tryptic digested by LC-MS/MS 
The obtained tryptic digests were analyzed according to LC-MS/MS, 
using a Q-TOF equipped with nano-spray source and analyzer hybrid 
quadrupole-time of flight, coupled to a chromatograph capillary 
UPLC equipped with a C18 column nano (Waters, Milan, Italy). The 
separation was conducted using water + 0.1% formic acid (eluent A) 
and acetonitrile + 0.1% formic acid (eluent B), and a linear gradient 
from 10 to 45% of B in 60 minutes, at a flow rate of 300 nl / min. 
Spectra were obtained in positive mode, over a range of m/z 500-
1800. The ions of greater intensity were selected automatically by the 
instrument software and subjected to fragmentation within the 
collision cell (dependent scan analysis), producing MS/MS spectra 
information on the sequence of the peptides analyzed. The range of 
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m/z analyzed in both modes (MS and MS/MS) was calibrated using 
the fragment ions of the peptide Glu-Fib. The correction of the 
calibration takes place in real time using a system that injects Lock 
Mass Glu-Fib continuously during the analysis. For protein 
identification, the following parameters were used: complete 
carbamidomethylation of cysteines and partial oxidation of 
methionines, peptide mass tolerance ±1.2 Da, fragment mass tolerance 
±0.9 Da, missed cleavages 2. 
 
3.2.5. Peptide mass fingerprinting (PMF) by MALDI-TOF-MS 
2 μl of the gel chromatography eluate containing the extracted protein 
were mixed with 2 μl of a matrix consisting of 1 mg of sinapinic acid 
dissolved in a mixture of distilled water and acetonitrile (1:1) plus 
0.1% trifluoroacetic acid. Aliquots of 2 μl of protein solution-matrix 
were loaded onto a MALDI plate. Spectra were acquired using a 
MALDI-TOF mass spectrometer (micro MX, Waters, Milan, Italy). 
The sample was bombarded by a pulsed laser beam with λ = 270 nm, 
resulting in the production of ions. The analysis was conducted in 
positive mode, using a TOF linear in the range of m/z between 20000-
170000 or between 2000-20000. The mass range analyzed was 
calibrated using an external standard mixture (2 μl) consisting of 
myoglobin [1 pmol/µl]: bovine serum albumin [1 pmol/µl] fortified 
with 1 µl of sinapinic acid in water:acetonitrile (30:70, v/v). Data were 
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acquired and processed by MassLynx software (Waters-Micromass). 
Protein identification was performed by searching in a nonredundant 
protein sequence database (NCBInr) using Mascot program 
(http://www.matrixscience.com), and results were considered 
significant if the resulting scores were higher than the threshold score 
indicated in the software. 
 
3.2.6. Vesicle Preparation 
Liposomes, ethosomes and PEVs were prepared using P50, Et, Trc or 
PG, empty or loaded with PC, as reported in Table 1. For liposomes 
and PEVs, all components were weighted in a glass vial, one after the 
other, and left hydrating for 2 hours in bidistilled water (59, 60). Then, 
the suspensions were sonicated (5 seconds on and 2 seconds off, 30 
cycles) with a high intensity ultrasonic disintegrator (Soniprep 150, 
MSE Crowley, London, UK), until clear dispersions were obtained. 
For ethosomes, P50 and PC were dissolved in Et under mixing at 700 
rpm. Bidistilled water was added slowly in a fine stream, under 
continuous stirring, in a well-sealed vial to avoid Et evaporation. The 
final suspension was sonicated as above. 
All suspensions were prepared under yellow light and kept in the dark 
at all times. 
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3.2.7. Vesicle characterization 
Vesicle dispersions were observed by a JEM1010 (Jeol Europe, Paris, 
France) transmission electron microscope (TEM) at 80 kV. The 
average diameter, polydispersity index (PI; a measure of the width of 
size distribution) and zeta potential of samples were determined by 
Dynamic and Electrophoretic Light Scattering using a Zetasizer nano-
ZS (Malvern Instruments, Worcestershire, UK). Samples diluted 
(1:100) in water or Trc/, PG/, Et/water mixtures at the same ratio used 
for vesicle preparation, were analysed 24 hours after their preparation, 
at a constant temperature of 25 °C. Vesicles were separated from the 
non-encapsulated drug by exhaustive dialysis: dispersions were loaded 
into dialysis tubing (300 kDa Float-A-Lyzer
®
 G2, Spectrum 
Laboratories Inc., DG Breda, The Netherlands) and dialysed against 
water or PE/water mixture for 2 hours at 25 °C, which was appropriate 
to allow the dissolution and consequent removal of the non-
encapsulated PC. Drug content and vesicle loading efficiency (E%), 
expressed as the percentage of the amount of drug initially used, were 
determined using a UV-visible spectrophotometer (Lambda25, Perkin 
Elmer, Monza, Italy) at 615 nm. 
 
3.2.8. X-ray diffraction 
Vesicle structure was studied by Small and Wide-Angle X-ray 
Scattering (SWAXS). SAXS and WAXS patterns were recorded 
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simultaneously using a S3-MICRO (Hecus X-ray systems, Graz, 
Austria) coupled to a GENIX-Fox 3D X-ray source (Xenocs, 
Grenoble, France) working at 50 Kv and 1 mA. This source produces 
a focused X-ray beam with λ=1.542 Å at Cu Kα-line with more than 
97% purity and less than 0.3% Kβ. The two detectors are position 
sensitive detectors PSD 50 (Hecus, Graz, Austria). The working q-
range were 0.01 ≤ q ≤ 0.6 Å−1, in the small angle, and 2.8 ≤ q ≤ 3.5 
Å−1 in the wide angle range, where q = (4 π sin θ)/λ is the modulus of 
the scattering wave vector, θ the scattering angle and λ the 
wavelength. Vesicular dispersions were loaded into thin-walled 1 mm 
glass capillaries for the scattering experiments. The diffraction 
patterns were recorded at 25 °C. All scattering curves were 
reproduced twice with subsequent calculation of the electron distance 
distribution, and yielded identical results. For the figures, a 
representative curve was selected, plotting the scattering intensity I as 
a function of the scattering vector q. SAXS patterns were analyzed 
using the MCG model developed by Pabst et al.(61). The analysis 
technique models the full q-range in the SAXS regime, including 
Bragg peaks and diffuse scattering. The bilayer electronic density 
profile is calculated as the sum of three gaussians, one corresponding 
to the methyl contributions and the other two corresponding to the 
polar heads. As a difference with respect to the model of Pabst et al. 
(61) we also incorporated a constant term through the hydrophobic 
part of the bilayer to give account for the methylene contribution. The 
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interbilayer ordering is taken into account considering the modified 
Caillé model as in the work by Pabst et al.(61). By this procedure, 
relevant structural parameters, as well as the distribution of electron 
density in the polar and apolar regions of membranes, were obtained. 
The model allowed fitting the SAXS pattern of bilayer-based 
structures, i.e. vesicles and lamellar phases. From the analysis, the 
membrane thickness was obtained through the definition dB = 2 (Zh + 
fwhm / 2), where Zh is the distance to the center of the bilayer of the 
polar head Gaussian with the corresponding full-width at half 
maximum fwhm. To derive the other parameters, we used 158.5 
electrons for the polar head and 261.9 electrons for the hydrophobic 
tails (based on the composition of P50). 
 
3.2.9. Confocal Laser Scanning Microscopy (CLSM) 
Vesicles were labelled by adding Rho-PE to the phospholipid mixture. 
The penetration extent and distribution of fluorescent PC in 
rhodamine-labelled vesicles was investigated ex vivo through full-
thickness human skin obtained from patients undergoing abdominal 
plastic surgery. The labelled colloidal dispersions (100 μl) were 
applied onto the skin (n = 6 per formulation) mounted on Franz 
vertical cells (diffusion area 0.785 cm2). Experiments were carried out 
in non-occlusive conditions, for 8 hours. After that, skin specimens 
were gently washed with distilled water, the diffusion area punched 
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out and rapidly frozen at -80 °C. Sections of skin (7 μm thickness) 
were cut with a cryostat (Leica CM1950, Barcelona, Spain) 
orthogonally (in the z axis) to the surface, and examined under a 
FluoView FV1000 inverted confocal microscope (Olympus, 
Barcelona, Spain) equipped with a Ultraviolet/Visible light laser. 
Using a UPlanSApo 20x objective NA 0.75, images with a field size 
of 1024 × 1024 μm were generated. PC and rhodamine were excitated 
at 600 nm and 559 nm, and detected at 640 nm and 578 nm, 
respectively. 
 
3.3.0. Scanning Electron Microscopy (SEM) 
At the end of Franz experiments (as above), skin specimens were 
gently washed, the treated area punched out, immediately immersed in 
PBS 0.2 M, pH 7.3, and fixed with Karnovsky’s paraformaldehyde-
glutaraldehyde solution. After fixation, samples were dehydrated in 
graded ethanolic solutions (30, 50, 70, 96 and 100%, v/v), subjected to 
critical point drying, and coated with gold to prevent sample charging. 
Samples were visualized under a scanning electron microscope (SEM) 
Hitachi S4800 (Madrid, Spain). 
 
3.3.1. Statistical analysis of data 
Data analysis was carried out with the software package R, version 
2.10.1. Results are expressed as the mean  standard deviation (SD). 
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Multiple comparisons of means (Tukey test) were used to substantiate 
statistical differences between groups, while Student’s t-test was used 
for comparison between two samples. Significance was tested at the 
0.05 level of probability (p). 
 
3.4. Results and discussion 
The complete purification of PC from microalgae biomass is a 
complex procedure resulting in a very expensive commercial product 
(62). To obtain a suitable product available for pharmaceutical 
purposes, we extracted PC from AfaMax
®
 simplifying the method by 
Benedetti et al. (57). for an efficient separation and purification of the 
protein. We obtained 40% yield (w/w) of PC from AfaMax® extract. 
UV-visible spectrophotometric reading of the extracted protein, in 
comparison with commercial PC (C-PC from Spirulina sp.; Sigma-
Aldrich, Milan, Italy), and SDS-PAGE analysis were performed to 
evaluate the purity and content of PC in the extract. Two main bands 
of purified PC were visible in SDS-PAGE under reduced conditions, 
corresponding to α and β subunits with the predicted molecular 
weights of about 18 and 19 kDa, respectively (Figure 1). Furthermore, 
the UV-visible spectrum revealed the characteristic absorption band of 
PC at λmax 620 nm (data not shown). The identification of α and β 
subunits separated by SDS–PAGE was also confirmed using MALDI 
mass spectrometry. 
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Figure 1. SDS PAGE analysis (A) and MALDI-TOF spectrum (B) of 
purified phycocyanin from AfaMax
®
 extract. 
 
 
 
 
 
 
 
The representative MALDI-MS spectrum recorded is displayed in 
Figure 1, where two main peaks identifiable as α- and β-PC subunits 
were detected (m/z 17715.8716 and 19209.4602, respectively). 
Moreover, in the low m/z region of the spectrum, the corresponding 
doubly charged ions were also present. Tryptic digestion of proteins 
contained in the SDS-PAGE bands led to consolidate the protein 
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identification by PMF using MALDI-TOF and/or by Peptide fragment 
fingerprinting (PFF) using nano-LC/MS/MS. Specific m/z values were 
obtained for each protein band and the corresponding MS/MS data to 
confirm the protein. Both Mascot and Protein prospectors were used 
as search engines. The gel band at 18 kDa was successfully attributed 
to the α PC subunit. Eight specific m/z values used in protein search 
were compatible with tryptic peptides from this protein (mass 
accuracy between 1 and 15 ppm), obtaining a sequence coverage of 
70%. These data permitted an unambiguous identification of α PC 
subunit. The second band at 19 kDa was successfully attributed to the 
β PC subunit. Fourteen specific m/z values used in protein search were 
compatible with tryptic peptides from this protein (mass accuracy 
between 1 and 15 ppm), obtaining a sequence coverage of 71%. Thus, 
unambiguous identification of the β PC subunit was obtained. Our 
results are in conformity with previous reports on the α and β subunits 
of PC from blue-green algae (63, 65). Altogether these results indicate 
a ~ 90% purity of PC in the purified blue powder obtained from 
AfaMax
®
 extract.Once the protein was successfully extracted, purified 
and identified, it was encapsulated in different vesicular nanocarriers: 
liposomes, ethosomes and PEVs, prepared by direct sonication, 
without the use of any organic solvents. Sample composition is 
reported in Table 1. 
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Table 1. Composition of vesicular dispersions. 
Components Liposomes Trc-PEVs PG-PEVs Ethosomes 
P50 60 mg 60 mg 60 mg 60 mg 
PC 10 mg 10 mg 10 mg 10 mg 
Trc  0.2 ml   
PG   0.2 ml  
Et    0.2 ml 
water 1 ml 0.8 ml 0.8 ml 0.8 ml 
 
 
Table 2. Properties of P50 vesicles: mean diameter, polydispersity 
index (PI), and zeta potential (ZP). Values are the means  standard 
deviation (n =6). 
  Size 
(nm  SD) 
PI 
ZP 
(mV  SD) 
Liposomes Empty 64±3 0.21 -63±2 
 PC 124±5 0.22 -39±2 
Trc-PEVs Empty 67±3 0.20 -45±2 
 PC 187±4 0.27 -27±5 
PG-PEVs Empty 60±4 0.26 -45±2 
 PC 177±6 0.26 -24±3 
Ethosomes Empty 61±2 0.25 -54±4 
 PC 142±7 0.29 -26±6 
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Characteristic parameters of vesicle formulations are summarized in 
Table 2. 
Empty vesicles were always smaller than the corresponding protein-
encapsulated ones, probably because the large PC molecule interacts 
with bilayer polar regions increasing its curvature and, consequently, 
the size. Further, it was apparent that, in empty vesicles, the presence 
of the PE did not alter vesicle size, whereas PC conventional 
liposomes showed the smallest mean diameter (p < 0.05). The mean 
size of vesicles increased slightly using Et, and more significantly 
using Trc and PG, probably because PC interacts with bilayer surface 
increasing its curvature and these PC-phospholipid polar head 
interactions are modulated by PE polarity. Zeta potential values were 
similar for all empty PEVs (~ -47 mV) and became more negative for 
empty liposomes (-63 mV), showing a negative surface charge due to 
P50 anionic lipidic fractions (49, 66). It has to be noted that the PC 
loading of vesicles resulted in less negative zeta potential values, 
because at a pH (~ 5) below its isoelectric point (pI ~5.8), PC carries a 
net positive charge. 
Dialysed vesicles showed slightly larger size than the corresponding 
non-dialysed samples (data not reported). As known, dialysis can 
induce an increase in vesicle size as a consequence of the osmotic 
stress during this purification procedure. However, the increase was 
not statistically significant. 
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All P50 vesicles were able to incorporate an acceptable amount of PC 
(around 40%), without statistical differences among the various 
formulations. Indeed, the PEs did not affect E%. PC is a large 
hydrosoluble molecule that is present at the same concentration in the 
internal and external medium of vesicles. Thus, the amount of 
encapsulated PC depends on the volume of vesicle aqueous 
compartment, which is usually low, and consequently E% (67). The 
presence of PE did not change the drug solubility and then, the 
amount of encapsulated drug. 
A preliminary investigation on vesicle formation and morphology was 
carried out by TEM (Figure 2). 
 
Figure 2. Phycocyanin-encapsulated liposomes (A) and Trc-PEVs 
(B). 
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Liposomes were spherical and unilamellar, while PEVs showed more 
irregular shape, in particular PG-PEVs (44), as previously reported for 
diclofenac PG-PEVs (46). On the other hand, Trc-PEVs appeared 
multilamellar. 
To gain further information about salient features of the prepared 
vesicular systems regarding their geometrical properties and 
morphology, SAXS and WAXS were used, as they are among the 
principle techniques for the microscopic characterization of self-
assembling structures in the nanometer scale. SAXS experimental data 
was fitted to a bilayer model with interbilayer correlations (see the 
experimental part for further details). In Figure 3 the resulting fits are 
shown as lines. The reduced chi square (2 = 1 for purely statistical 
noise) values were below 2 (nearly perfect fitting), except for the 
samples containing Trc where it was around 10. However, the quality 
of these fits was still quite good. 
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Figure 3. Small angle X-ray diffraction patterns (SAXS) of 
liposomes, ethosomes and PEVs. For the sake of clarity the curves of 
empty liposomes and ethosomes have been omitted, as 
superimposable to the corresponding phycocyanin (PC) loaded 
vesicles. 
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Table 3. Selected fitting parameters and derived parameters for SAXS 
curves. All distances are given in nm. 
 
 Liposomes 
+PC 
Ethosomes 
+PC 
PG-PEVs 
+PC 
Trc-PEVs 
+PC 
1
 d 5.040.5 4.510.5 4.930.1 5.190.05 
2
 
 
1.820.2 1.380.2 1.150.2 0.460.05 
3
 N
 2.70.3 2.50.3 14.02 35.15 
4 
h
 
0.330.005 0.280.005 0.210.005 0.320.01 
5
 Zh 1.830.01 1.720.01 1.770.01 1.730.05 
6
 dc 1.440.02 1.390.02 1.520.02 1.360.06 
7
 dB 4.460.04 4.100.04 4.040.04 4.220.13 
8
 dw 0.580.5 0.400.5 0.890.1 0.980.05 
1
 d repetition distance; 
2
  Caillé parameter; 3 N number of correlated lamellae; 4 h polar 
head amplitude; 
5
 Zh polar head distance to the center of the bilayer; 
6
 dc hydrophobic chains 
layer half-thickness; 
7
 dB bilayer thickness; 
8
 dw water layer thickness. 
 
As evident from the SAXS pattern, showing a diffuse scattering with 
broad symmetric band, empty liposomes, ethosomes and PG-PEVs 
can be considered unilamellar. The addition of PC slightly modified 
the scattering curves, but the derived parameters for the bilayer were 
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very close. This was not true in the presence of PG. Indeed, PG-PEVs 
loading PC showed a correlation, even though the uncorrelated 
bilayers were predominant, thus indicating the presence of a mixed 
population of multilamellar and unilamellar vesicles. On the other 
hand, Trc-PEVs showed stronger correlation, typical of multilamellar 
vesicles. The diffraction intensity decreased due to the decrease in the 
number of layers induced by PC presence. 
In the case of empty liposomes, ethosomes and PG-PEVs, none of the 
penetration enhancers noticeably affected bilayers features and 
correlated parameters. They were unilamellar, soft vesicles with low 
number of correlated layers (N ~ 2), the Caillé parameter η ~ 1.6, and 
bilayer thickness dB ~ 4.2 nm. Additionally, they did not perturb 
strongly Zh (~1.7), that is, the separation between the polar heads and 
the center of the bilayer. It is noteworthy that the loading of PC did 
not alter the above parameters for liposomes and ethosomes. In 
contrast, a strong effect was observed with Trc (Zh = 1.88), which 
converted the vesicles in relatively stiff multilamellar vesicles 
(decrease in Caillé parameter, η = 0.16, and high number of correlated 
layers, N = 20.5). The additional presence of PC seemed to slightly 
reduce the stiffness of Trc-PEVs bilayers (Figure 3 and Table 3). This 
is in good agreement with TEM analyses, where Trc-PEVs were seen 
as multilamellar (Figure 2B). Regarding PG-PEVs loading PC, the 
simultaneous presence of PG and PC caused a partial multilamellarity, 
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implying a certain stiffness, as also confirmed by a high N value 
(=14). 
The presence of Trc and PG in combination with PC, determined an 
increase in vesicle size and lamellarity that corresponded to a 
stiffening of the bilayers. This was not true for Et that gave larger 
vesicles but still unilamellar, thus confirming the soft and malleable 
nature of ethosomes (68) In addition, the multilamellarity of Trc-PEVs 
and PG-PEVs (partial) loading PC was reflected in the interbilayer 
water thickness dw, which was almost 2-fold higher than liposomes 
and ethosomes. Lamellar Bragg distances (d; Table 3) were all around 
5.0 nm for both empty and loaded samples. Concerning multilamellar 
Trc-PEVs, the addition of PC seemed to increase the interlamellar 
distance. This increase was accompanied by a strong increase in the 
hydration of the polar heads (h = 0.32 vs 0.22 for empty vesicles). 
The addition of PC also produced an appreciable reduction in the 
hydrophobic bilayer thickness (dc = 1.36 vs 1.62 for empty vesicles; 
also reflected in the decrease in Zh). However, the total bilayer 
thickness dB remained almost unchanged, due to the increase in the 
polar head region, h. This is in accordance with the nature of PC 
locating mainly in the polar head region of the bilayers. 
Overall, from Table 3 it can be inferred that the simultaneous presence 
of PEs and PC caused a decrease in the bilayer thickness dB, mostly 
due to a decrease in the hydration of the polar heads (compare h of 
liposomes vs the other vesicular systems), correlated to a predominant 
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interaction of hydrophilic PEs and PC with the polar region of 
bilayers. As expected, the SAXS spectra did not show any distinct 
peaks for non-organized structures in this range of distances, 
indicative of liquid-crystalline state (Lα). However, the electronic 
density profiles (data not shown) could be compatible with partial 
segregation of the terminal methyl groups in the case of ethosomes 
and PG-PEVs loading PC.  
In our previous work, liposomes were capable of improving in vivo 
anti-inflammatory activity of PC in a dose-dependent fashion, as a 
consequence of enhanced PC skin delivery obtained using liposomal 
carriers (55). Our further studies, suggest that PEVs possess a superior 
ability to improve dermal deposition and transdermal permeation, with 
respect to conventional liposomes (44, 49). Indeed, drug penetration 
through the skin depends strongly on its physicochemical properties 
and on the carrier in which it is applied. In ethosomes and PEVs, the 
presence of the water cosolvent, influences both the vesicle properties 
and the barrier function efficacy of the skin, facilitating the active 
compound passage and accumulation into the skin (68, 69). In the 
present study, a CLSM study was carried out to evaluate the vesicle 
formulations’ ability to allow PC penetration and distribution through 
human skin. The skin was observed microscopically after 8 hours of 
ex vivo treatment with fluorescent PC-loaded rhodamine-labelled 
vesicles. Images of the skin treated with empty vesicles did not reveal 
any fluorescence signal, and skin autofluorescence was not detected. 
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Figure 4. Cross-sectional images obtained following treatment with 
phycocyanin-encapsulating liposomes, ethosomes, PG-PEVs and Trc-
PEVs. 
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Figure 4 consists of four representative, optical cross-sections, 
selected from several images and several different zones of treated 
skin. In the lefthand, we reported rhodamine fluorecence (red), in the 
middle PC florescence (yellow) and in the righthand the merge of the 
two probes’ fluorescence: the orange color shows the probes’ 
superposition. The observed fluorescence accumulation across the 
stratum corneum and viable epidermis was relatively homogeneous in 
all the tested formulations, and was higher than that observed in the 
dermis that exhibited a less intense and diffuse staining. Images 
indicate that all vesicles were able to deliver the protein deeply to the 
skin. In particular, PEVs showed a penetration ability greater than 
liposomes and ethosomes, which presented a dominating staining in 
the stratum corneum, as compared to that in the viable epidermis. The 
dual image analysis by the probe colocalization provides a clear 
illustration of the possible vesicle distribution (orange fluorescence). 
These results indicate that PEVs, especially PG-containing vesicles, 
are promising carriers for the delivery of the high MW PC molecule to 
the deep skin layers, where its anti-inflammatory activity needs to be 
exerted. 
In order to better evaluate the vesicle-skin interaction, we observed 
immobilized skin by SEM (48, 58) Images visualize the immobilized 
tissue in three-dimensional form (Figure 5). 
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Figure 5. SEM images of untreated (a) and liposome- (b), ethosome- 
(c) and PEV- (d) treated skin 
 
 
 
 
Untreated human skin tissue was first imaged as a control. The 
epidermis ultrastructure of the untreated tissue appeared compact and 
thin, whereas following application of different PC vesicles, skin 
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appeared swollen. In particular, skin treated with PEVs showed 
evident intercellular spaces of the stratum corneum indicating a high 
hydration. There is a 10–20% increase in thickness of the SC. 
Hydration is known to improve the skin permeability and could 
enhance penetration of macromolecules, such as proteins. A 4-10-h 
hydration period is enough to enhance transcutaneous penetration of 
large biomacromolecules without permanently damaging the skin 
(71). SEM images validated our hypothesis regarding the mechanism 
of PEV-skin interactions: PEVs, thanks to a synergic effect of PE and 
phospholipid vesicles, partially penetrate intact until the epidermis and 
partially fuse with the intercorneocyte lamellar structure of stratum 
corneum hydrating it. 
 
3.5. Conclusion 
PC is a natural biliprotein with important anti-inflammatory and anti-
oxidant activities, but its use in pharmaceutical applications is limited 
by its high cost. Results of this work confirmed the feasibility of 
obtaining from a commercial extract a product suitable for 
pharmaceutical uses, with 90% of purity degree. The encapsulation of 
extracted PC into PEVs, especially PG-PEVs, facilitated the 
accumulation of the high molecular weight drug into the deep skin 
layers where drug needs to exert its action. Thanks to their innovative 
formulation containing a PE into vesicle structure, PEVs can act 
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simultaneously as penetration enhancers and carriers facilitating the 
(trans)dermal delivery of PC protein. 
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4.0 Respiratory system 
In the last year of my PhD thesis I started a new formulation study in 
Paris, Université Paris Sud XI, Chatenay-Malabry. During this period 
I prepared and characterized new hybrid lipid-polysaccharide 
nanocarriers for curcumin pulmonary delivery composed of curcumin 
loaded-liposomes modified with chitosan. Liposomes, as pulmonary 
drug delivery carriers, have been studied for years and used to deliver 
phospholipids to the alveolar surface for the treatment of lung disease 
and systemic diseases. Inhaled liposomes reach the alveoli, achieving 
a prolonged pulmonary retention time of drug and increasing the 
efficacy of drug in vivo (72-74). Moreover, phospholipids are 
absolutely biocompatibile and have also beneficial effects for lung 
surfactants, often compromised during this disease. Thus, liposomes 
protect encapsulated curcumin from external environment and have 
the advantage of vehiculating the poor soluble curcumin in an aqueous 
environment with a consequent enhanced bioavailability. Liposome 
surface was coated with chitosan in order to improve liposome 
stability, and mucoadhesion (75-77). In fact, chitosan is a polycationic 
polysaccharide that possesses promising properties in drug delivery, 
such as biocompatibility and biodegradability that make it an 
attractive vehicle for designing adequate dosage forms for pulmonary 
drug delivery. Moreover, chitosan is a bioadhesive polymer that could 
avoid curcumin-liposome clearance by the mucociliary escalator. 
Curcumin, useful to limit cystic fibrosis pulmonary disease 
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progression, can be pulmonary delivered by using chitosan coated 
liposomes. 
Pulmonary administration of drugs, in the treatment of localized 
diseases within the bronchi, allows to delivery high amount of the 
drug into the diseased regions. The highly efficient clearance of 
mechanisms of the human respiratory tract causes a fast drug action 
after dosing. Therefore, an adequate carrier vehicle may facilitate the 
drug transport to the lung, prolonging its retention time in the epithelia 
tissue, avoiding its degradation at pH 7.4, and improving its local 
absorption, thus maintaining therapeutic concentrations of the drug 
within the lung tissues. 
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5.0. Chitosomes as drug delivery system 
for curcumin pulmonary administration 
5.1. Introduction 
Cystic fibrosis is chronic, progressive, and usually fatal disease caused 
by defective function of a gene product, Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR). Cystic fibrosis is 
characterized by abnormal chloride transoport in many tissues, 
including lung, pancreas, gastrointestinal tract, liver, sweat glands, 
and male reproductive ducts (78). 
Current therapeutic approaches to pulmonary cystic fibrosis primarily 
focus on restoring the function of the CFTR, stimulating alternative 
chloride channels, inhibiting sodium absorption, and utilizing 
hyperosmotic agents to rehydrate the airway surface. An approach to 
rescue CFTR function in the airways epithelia is corrects the defects 
associated with mutant CFTR proteins or alternatively enhance the 
function of the CFTR chloride channel (79). 
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-
dione) is a non-toxic bioflavonoid that have antioxidant activity, and 
inhibits such mediators of inflammation as NFκB, cyclooxygenase-2, 
lipooxygenase, and inducible nitric oxide synthase. Curcumin are able 
to rescue mutant gene (ΔF508) CFTR in airway epithelial cells and 
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mouse models. Although other studies have underlined that curcumin 
can produce an increase in CFTR channel activity. Its action 
mechanism is controverts but it is actually able to stop cystic fibrosis 
pulmonary disease progression thank to its ability to enhance CFTR 
channel function synergically to its antioxidant and antinflammatory 
activity. 
In this work, aiming at improving curcumin solubility and its time 
retention into lung tissue, a novel plymer surface-modified liposome 
formulation was designed. In fact, liposomes thanks to their are high 
biodegradable and biocompatible are a suitable lung delivery system 
that offer advantages of local administration, uniform deposition and 
high surface distribution of active drug. Liposomes coated with 
suitable polymers can improve drug bioadhesion, modify 
pharmacokinetics, and protect the encapsulated drug from enzymatic 
attack. Among the various polymers, able to interact with liposome 
surface chitosan (CH) possess good mucoadhesive properties and are 
able to their protect and stabilize. Moreover, it has already 
successfully used to coat liposome formulations (80). Surface 
modification of liposomes with CH has been shown to prolong their 
residence time in the airways in comparison with uncoated ones, 
thanks to ionic interactions between positive amino groups of the 
polymer and the negative mucus gel layer (81).  
Liposomes formulations were prepared using a mixture of soy lipids 
(Phospholipon 50, P50) and curcumin and they were used as control. 
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Liposomes surface were then coated by adding chitosan to control 
formulation. Prepared vesicles were thoroughly characterized by size, 
surface charge and loading and aggregation capacity. The in vitro 
cytotoxicity, cellular uptake, induced by the different liposomes were 
all assessed using the Calu-3-based model of lung epithelium (82).  
 
5.2.Materials and Methods 
5.2.1. Materials 
A commercial mixture of soybean phospholipids (Phospholipon
®
 50, 
P50, with 45% phosphatidylcholine and 10-18% 
phosphatidylethanolamine, maximum 3% triglycerides, maximum 
0.25% D,L-a-tocopherol, and the remaining part (37%) lipids: fatty 
acids, glycolipids, phosphatidylinositol, etc) was kindly supplied by 
AVG (Milan, Italy) and Lipoid GmbH (Ludwigshafen, Germany). 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine 
B sulfonyl) ammonium salt (rhodamine-phosphoethanolamine, Rho-
PE) was purchased from Lipoid GmbH (Ludwigshafen, Germany). 
Chitosan (CH) low molecular weight, curcumin (CUR) (1,7-bis(4-
hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) and all others 
products were purchased from Sigma (Milan, Italy). 
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5.2.2. Liposome preparation 
Curcumin (5 mg/ml) was dispersed in the water and added to the flask 
containing P50 (60 mg/ml). Lipids were left swelling in the solution 
overnight (62) and sonicated for 2 minutes (5 seconds on and 2 
seconds off) using a Soniprep 150 ultrasonic disintegrator (MSE 
Crowley, United Kingdom). 
Each vesicle suspension was purified from the non-incorporated drug 
by dialysis against distilled water at 4°C for 4 hour, using dialysis 
tubing (Spectra/Por
®
 membranes: 12–14 kDa MW cut-off, 3 nm pore 
size; Spectrum Laboratories Inc., Ranchio Domingo, USA). 
Liposome formulation (5 ml) was diluited in distiled water (10 ml) to 
obtain the same drug concentration of chitosomes. 
 
5.2.3. Chitosome preparation 
Appropriate amount of chitosan (50 mg/ml) was dissolved under 
stirring in acetic acid (0.1%) aqueous solution. Dyalised CUR loaded 
liposomes (5 mL) were slowly added to the CH dispersion (10 mL) 
under stirring at 25°C to obtain the final chitosomes. Dispersions were 
ultracentrifuged at 40000 RPM for 4 h at 4°C to eliminate the excess 
of chitosan and washed three times with distilled water. 
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Table 1. Composition of curcumin liposomes and chitosomes 
 CUR 
(mg/mL) 
P50  
(mg/mL) 
CH 0.5% 
(mg/mL)  
 
Liposomes 
 
1.7 
 
20 
 
- 
Chitosomes 1.7 20 3.3 
 
5.2.4. Liposomes and chitosome charaterisetion 
Formation and morphology of vesicles and chitosomes were evaluated 
by Transmission Electron Microscopy (TEM) using a JEOL JEM-
1400 microscope (CNRS, Gif s/Yvette, France) operating at 80kV. 
Average diameter and polydispersity index (PI) of the samples was 
determined by photon correlation spectroscopy using a Zetasizer nano 
(Malvern Instrument, Worcestershire, United Kingdom). Before 
counting, the samples were diluited with distilled water. Samples were 
backscattered by helium–neon laser (633 nm) at an angle of 173
◦
 and 
at constant temperature of 25
°
C. Zeta potential was estimated using 
the Zetasizer nano by means of the M3-PALS (phase analysis light 
scattering) technique, which measures the particle electrophoretic 
mobility in a thermostated cell. All the samples were analyzed 24 h 
after their preparation. 
Quantitative determination of phospholipids was carried out using an 
enzymatic test BIOLABO
®
 (Maizy, France). Vesicle dispersion (10 
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µl) was added to the reagent and obtained solution kept in an 
incubator for 10 minutes at 30
°
C and thus, analyzed at 500 nm using a 
UV spectrophotometer (Beckman DU 7400, Paris, France). 
Aggregation efficiancy (AE%) was calculated using equation 1: 
Eq. 1 AE% = [Phdialysed]/[Phundialysed] x100  
were Phdialysed is phospholipid concentration after dyalisis and 
Phundialysed is phospholipid concentration before dalysis. The 
quantitative determination of chitosan was performed by colorimetric 
test based on the formation of colored complexes between the amino 
groups of the chitosan and the anionic groups of the Cibacron Brilliant 
Red 3B-A (83). Chitosan amount was measured in supernatant and 
precipitate after ultracentrifugation. Coating efficiency (CE%) was 
calculated using equation 2: Eq. 2 CE% = 
[CHcentrifugated]/[CHuncentrifugated] x100  
were CHcentrifugated is chitosan concentration after centrifugation and 
CHuncentrifugated is chitosan concentration before centrifugation. CUR 
entrapment efficiency (EE%), expressed as the percentage of the 
amount of CUR found after purification respect that initially used, was 
determined by UV analysis after distruption of vesicles by methanol 
dilution (1/500). CUR content was quantified at 424 nm using a 
spectrophotometer Beckman DU 7400 (Paris, France). 
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5.3. Calu-3 cell line culture 
The Calu-3 cell line was obtained from the American Tissue Type 
Collection (catalog number HTB-55) and maintained at 37°C and 5% 
CO2 in a humidified atmosphere. Cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, Lonza, Levallois, France) 
supplemented with 50 U/mL penicillin, 50 U/mL streptomycin, and 
10% fetal bovine serum (Lonza, Levallois, France). The medium was 
changed every four days and cells were passed weekly at a 1/3 split 
ratio using Trypsine-EDTA. 
 
5.3.1. Cell viability assay 
The in vitro cytotoxicity of the liposomes and chitosomes was 
evaluated using the 3-[4,5-dimethylthiazol-2-yl]-3,5 diphenyl 
tetrazolium bromide (MTT) test. This assay depends on the cellular 
reductive capacity to metabolize the MTT to a highly colored 
formazan product. Cells were seeded in 200 μL of growth medium 
(1.25 × 105 cells/mL) in 96-well plates (TPP, Zurich, Switzerland) 
and preincubated for 24 hours to recover. Then, 100 μL of freshly 
prepared samples dispersions in fetal bovine serum-containing cell 
culture medium were added immediately after dilution to different 
drug concentrations (150-0.075 g/mL). The formulations were 
assayed for toxicity over 4, 24, and 72 hours of incubation. After the 
incubation period, 20 μL of a 5 mg/mL MTT solution in phosphate-
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buffered saline was added to each well. After 2 hours, the culture 
medium was gently aspirated and replaced by 200 μL of dimethyl 
sulfoxide in order to dissolve the formazan crystals. The absorbance 
of the solubilized dye, correlates with the number of living cells, was 
measured with a microplate reader (LAB Systems Original Multiscan 
MS, Helsinki, Finland) at 570 nm. All experiments were repeated at 
least three times and in triplicates. Results are shown as percent of cell 
viability in comparison with non-treated control cells (100% viability). 
 
5.3.2. Statistical analysis of data 
Results are expressed as the mean  standard deviation (SD). Analysis 
of variance (ANOVA) and Bartlett’s test for homogeneity of variance 
were performed using SPSS version 17.0 for Windows (SPSS Inc., 
Chicago, United States). Post hoc testing (P < 0.05) of multiple 
comparisons was performed using the Scheffe test. Differences were 
considered significant at the 0.05 level of probability (p). 
 
5.4. Results and discussion 
5.4.1. Liposome and Chitosome Characterization 
Negative liposomes were prepared using a commercial mixture of 
phospholipids (P50, 60 mg/mL) and curcumin (CUR, 5 mg/mL). by 
Lipid mixture were hydrated with PBS, left swelling for 12 hours and 
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then sonicating it. To further improve stability as well as to achieve a 
mucoadhesive formulation, the surface of P50 liposomes was coated 
with CH (84). Chitosan coated liposomes (so called chitosomes) were 
previously prepared by several authors (51, 80, 75-77) 
Liposome and chitosomes formation and their structure were 
confirmed by TEM. Figure 1. 
 
Figure 1. Negative stain electron micrographs of (a) curcumin loaded 
liposomes and (b) chitosomes. 
 
   
 
Mean size and zeta potential of liposomal formulations are shown in 
Table 2. Mean diameter of empty liposomes was 100±3 and samples 
was low polydispersed (P.I. ~ 0.18). When CUR was added in the 
formulation, vesicle size sligtly increased (10%) but polydispersity 
index became constant. Chitosome diameter increased up 199±18 nm 
due to the formation of coating polymer layer. 
Zeta potential of liposomes was strongly negative (-51 mV, Table 2) 
because P50 is a mixture of phosphatidylcholine, other phospholipids 
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and fatty acids. At pH ~6 the negative phosphate residues of the 
phospholipids were distribuited to membrane surface leading a 
negative potential. Moreover, fatty acids, could contribute to the 
negative value of zeta potential (84). Positively charged polymeric CH 
molecules can easly interact with negative phosphate group of 
liposomes surface allowed stable, electrostatic interactions. The 
change of the zeta potential of chitosomes to positive values (+48 mV) 
confirmed the formation of polymer coating on the liposome surface. 
This strongly positive zeta potential value may represent stability 
against aggregation processes due to the electrostatic repulsion among 
vesicles in dispersion. 
 
Table 2. Mean diameter, Polydispersity Index (PI) and Zeta Potential 
of empty and CUR loaded liposomes empty and CUR loaded 
chitosomes. 
 
Sample  Mean diameter 
(nm) 
P.I. Zeta potential 
(mV) 
Liposomes  empty 100±3 0.18 -58±1 
Liposomes CUR 111±3 0.17 -51±4 
Chitosomes empty 398±8 0.232 +26±1 
Chitosomes  CUR 199±18 0.18 +48±2 
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CUR entrapped efficiency of liposomes (86%) was sligtly higher than 
that of chitosomes (78%) due to a lost of drug during 
ultracentrifugation process. 
Quantitative determination of the lipids was performed using an 
enzymatic kit (Biolabo
®
) that measured only the effective amount of 
phosphatidylcholyne in dispersion. Using this concentration we 
calculated the vesicles aggregation efficiency (%). AE% of liposomes 
was hight (92%) confirming a good ability of phospholipipds to form 
closed bilayer vesicles in presence of CUR. AE% of chitosomes was 
lower (80%) probably because a little amount (10%) of uncoated 
phospholipids vesicles was lost during centrifugation procedure. In 
fact, too the drug EE% of chitosomes was lower than that of 
liposomes. The colorimetric determination of chitosan was carried 
before and after ultracentrifuge on the pellet and the supernatant 
obtained from chitosome dispersion. Chitosan coating efficiency (%) 
was 66%. It rapresents the effective amount of chitosan able to stably 
interact with vesicle surface. Chitosan on vesicle surface stabilized the 
dispersion and could improve vesicle mucoadhesion and drug 
bioavailability. However, it is important to eliminate the excess of 
chitosan in dispersion because it can form polymer aggregates that 
precipitated. 
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Table 3. Entrapment Efficiency (EE%), Coating Efficiency (CE%) 
and Aggregation Efficiency (AE%) of empty liposomes, CUR loaded 
liposomes and chitosomes. 
 
Sample  EE (%) AE (%) CE (%) 
Liposomes CUR 86±4 92±3  
Chitosomes  CUR 78±3 80±6 66±4 
 
 
5.4.2. Effect of liposomes and chitosomes concentration and surface 
chemistry on cell viability assay 
Calu-3 cell viability was studied as a function of drug concentration 
(0.15-0.00075 g/mL) using the MTT assay. This quantitative 
colorimetric test is based on the ability of viable cells to metabolize 
the water-soluble dye (MTT) into a colored formazan salt. Liposomes 
toxicity and cell viability was investigated for 4, 24 and 72 hours. 
After incubation with CUR loaded liposomes cell viability was always 
higher than 80% even at the highest drug concentrations. Cell viability 
was not compromise by drug and phospholipids concentration (Figure 
2). Chitosomes toxicity was very low at 4 hours of incubation and the 
association between phospholipids and chitosan seem to reduce the 
toxicity and stimulate cell proliferation (Figure 3). 
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Figure 2. Calu-3 cell viability (MTT assay) after exposure to 
(a)curcumin loaded liposomes, and (b) chitosomes as a function of 
time. Each experiment was repeated for three times. Results are 
expressed as percentages of absorption for treated cells (±standard 
deviation) in comparison with untreated control cells. 
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Successively, viability decreased gradually. Chronical exposure of 
cells (72 h) to chitosomes increased cell mortality up to 80% 
compared to untreated control cells (100% viability). Also in this 
case cell viability was not affect by drug, phospholipids and 
chitosan concentrations. For both the tested formulations the 
toxicicy was always acettable and mortality did not overcam 20% 
except for the highest drug and phospholipids concentrations (drug 
0.15 g/ml). The presence of chitosan in formulation did not change 
mortality values. 
 
5.5. Conclusions 
Chitosomes were prepared by using a mixture of fluid soy 
phosphatidylcholine and others fatty acids (P50), chitosan as coating 
polymer have a mean diameter around 200 nm that is suitable for 
pulmonary delivery. They showed a good capability to incorporate 
high quantity of curcumin also retained in high amount after the 
coating procedure. Chitosomes induce low toxicity even at hight 
concentration and time retentions in Calu-3 cells. These outcomes 
represent a base condition for further studies, in order to evaluate their 
biological properties and to assess in vivo activity in infected animal 
models.
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6.0. Final discussion 
In this thesis work were prepared and characterized liposomes and 
liposomes modified with a coating of chitosan called chitosomes. 
Through these structures were conveyed drugs of natural origin with 
anti-inflammatory and antioxidant properties: quercetin,phycocyanin 
and curcumin. The liposomes loading quercetin and phycocyanin are 
designed for a topical application and were tested on new born pig 
skin. Liposomes and chitosomes loading curcumin are designed for 
pulmonary delivery as a cure for cystic fibrosis. In this case, has been 
tested the toxicity of the system using a model of lung tissue using 
Calu-3 cells. 
The drug delivery via liposomes and chitosomes improves the 
retention time of the drug and increases its stability. Studies continue 
with biocompatibility and in vivo tests.
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